You are here: Home » News-CM » Companies » News
Business Standard

Natco Pharma launches HEPCINAT in Nepal

Capital Market 

Its first generic version of sofosbuvir in Nepal

has launched the first generic version of sofosbuvir in Sofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences, Inc., under its brand Sovaldi. Natco priced its generic medicine at an MRP of Rs 19,900 for a bottle of 28 tablets in

Natco markets generic sofosbuvir under its brand HEPCINAT. Natco hopes to launch HEPCINAT in India soon, subject to approval from the Drugs Controller General of India (DCGI). Natco had recently signed a non-exclusive licensing agreement with Gilead Sciences, to manufacture and sell generic versions of its chronic hepatitis C medicines in 91 developing countries.

Powered by Capital Market - Live News

First Published: Mon, March 09 2015. 09:20 IST